Please login to the form below

Not currently logged in
Email:
Password:

mRNA

This page shows the latest mRNA news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

Last year, AZ also paid 25m upfront in a research deal with German biotech Ethris to develop mRNA drugs for respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and idiopathic

Latest news

  • Morning brief: New biotech launched, Merck and Moderna expand collaboration and more Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

    The two companies have now added to their collaboration shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine. ... The two companies will now jointly develop Moderna’s mRNA-5671 in human studies, and plan

  • Lilly expands its immuno-oncology work with $1.8bn CureVac deal Lilly expands its immuno-oncology work with $1.8bn CureVac deal

    At the heart of the agreement is messenger RNA (mRNA) technology, marking the first time it has been broadly explored in the immuno-oncology capacity. ... With the aim to drive the potential future vaccines to market, CureVac will take responsibility for

  • Merck & Co signs cancer vaccines research deal for Keytruda Merck & Co signs cancer vaccines research deal for Keytruda

    The deal with Moderna Therapeutics will see it use the Cambridge, Massachusetts-based company's novel messenger RNA (mRNA)-based vaccine technology. ... Moderna's mRNA vaccine technology uses the unique mutations present in a patient's tumour to provoke

  • Sanofi forges $1.5bn cancer partnership with BioNTech Sanofi forges $1.5bn cancer partnership with BioNTech

    BioNTech has agreed to supply part of the mRNA material needed for development activities from its in-house manufacturing facility, and has also claimed the right to co-develop and ... commercialise two of the five mRNA therapeutics products with Sanofi

  • mRNA - message received mRNA - message received

    mRNA technology is fundamentally disruptive, enabling us to do things not possible with current approaches. ... and Alexion in mRNA therapeutics and Merck &Co and the Pasteur Institute for mRNA-based vaccines.

More from news
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    These early pioneers were largely focused on DNA-based gene delivery or the use of DNA anti-sense technologies to specifically inhibit mRNA translation. ... From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty

  • Deal Watch March 2017 Deal Watch March 2017

    In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product

  • Deal Watch September 2016 Deal Watch September 2016

    At a lower disclosed headline value of $310m BioNTech licensed its mRNA-based cancer vaccines platform to Genentech. ... Licence. mRNA personalised cancer vaccines; $310m upfront and near-term payments. 310+.

  • Deal Watch June 2016 Deal Watch June 2016

    The mRNA vaccines will also be assessed in combination with Keytruda on an exclusive basis. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).

  • Deal Watch November 2015 Deal Watch November 2015

    Sanofi will gain access to BioNTech's mRNA formulation technology to generate new cancer immunotherapies. ... Discover/ develop up to 5 cancer immunotherapies, each a synthetic mRNA mixture.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... As one of the pioneering companies in mRNA

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    CureVac appoints chief financial officer. Pierre Kemula joins the mRNA company’ s management board. ... Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

  • Dr Michael Watson appointed as president of Valera Dr Michael Watson appointed as president of Valera

    Dr Watson said: “ The potential for mRNA therapeutics to meaningfully address some of the world's most pressing infectious disease concerns is truly exciting. “

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics